Evidence map›Paper›PMID 41385014›Full record

ReviewArchives of microbiology2025

Lipid nanoparticle-based mRNA platforms for mucosal HIV vaccines: formulation advances, immune mechanisms, and translational pathways.

Narinderjit Singh Sawaran Singh, Ibrahim Saeed Gataa, Luma Hussain Saleh, Subbulakshmi Ganesan, V Kavitha, Laxmidhar Maharana, Renu Sharma, Mutabar Latipova, Nazira Madatova, Doniyor Jumanazarov and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Narinderjit Singh Sawaran SinghFaculty of Data Science and Information Technology, INTI International University, Persiaran Perdana BBN, Putra Nilai, 71800, Nilai, Malaysia. narinderjits.sawaran@newinti.edu.my.
Ibrahim Saeed GataaWarith Al-Anbiyaa University, Karbala, 56001, Iraq.
Luma Hussain SalehDepartment of Anesthesia Techniques, Health and Medical Techniques College, Alnoor University, Mosul, Iraq.
Subbulakshmi GanesanDepartment of Chemistry and Biochemistry, JAIN (Deemed-to-Be University), Bangalore, Karnataka, India.
V KavithaDepartment of Chemistry, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Laxmidhar MaharanaDepartment of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, India.
Renu SharmaDepartment of Chemistry, University Institute of Sciences, Chandigarh University, Mohali, Punjab, India.
Mutabar LatipovaUniversity of Tashkent for Applied Sciences, Str. Gavhar 1, 100149, Tashkent, Uzbekistan.
Nazira MadatovaThe Department of Pharmaceutical and Chemistry, Alfraganus University, 100190, Tashkent, Uzbekistan.
Doniyor JumanazarovUrgench State University, Kh. Alimdjan Str. 14, 220100, Urgench, Uzbekistan.
Aseel SmeratFaculty of Educational Sciences, Al-Ahliyya Amman University, Amman, 19328, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developing an effective HIV vaccine remains a major challenge in modern medicine. The majority of HIV transmissions occur across mucosal surfaces, yet the mucosal immune protection provided by current systemic vaccination strategies is limited. However, the potential of lipid nanoparticle (LNP)-based messenger RNA (mRNA) vaccines to revolutionize HIV prevention is a source of hope and optimism. Additionally, circular RNA (circRNA) represents an emergent platform that may offer potential for mucosal HIV vaccine development. This review examines the relationship between mRNA-LNP formulation science and mucosal immunology, with a focus on how adjuvant design, device engineering, and delivery methods interact to influence protective outcomes. We summarize the most recent research on mucosal delivery methods, including nasal, vaginal, rectal, and pulmonary routes, as well as formulation techniques to overcome obstacles such as mucus penetration, enzymatic breakdown, and epithelial absorption. We also examine how mRNA design (including nucleoside modification status) and prime-boost regimens influence the desired immunological outcomes, such as the induction of mucosal secretory IgA (SIgA), tissue-resident memory T cells (T

Indexed as

AIDS VaccinesHIV InfectionsLipidsNanoparticlesRNA, MessengerAdjuvants, ImmunologicAdministration, MucosalAnimalsHumansImmunity, MucosalLiposomesMucous MembraneAdjuvants, ImmunologicAIDS VaccinesLipid NanoparticlesLipidsLiposomesRNA, MessengerHIVLipid nanoparticlesmRNA vaccineMucosal deliveryMucosal immunityVaccine formulation

Identifiers

PMID41385014

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.